Free Trial

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals logo
$580.70 +1.09 (+0.19%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$580.25 -0.45 (-0.08%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
6
Buy
20

Based on 27 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 1 has given a sell rating, 6 have given a hold rating, 17 have given a buy rating, and 3 have given a strong buy rating for REGN.

Consensus Price Target

$817.67
40.81% Upside
According to the 27 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $817.67. The highest price target for REGN is $1,175.00, while the lowest price target for REGN is $547.00. The average price target represents a forecasted upside of 40.81% from the current price of $580.70.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REGN Analyst Ratings Over Time

TypeCurrent Forecast
9/1/24 to 9/1/25
1 Month Ago
8/2/24 to 8/2/25
3 Months Ago
6/3/24 to 6/3/25
1 Year Ago
9/2/23 to 9/1/24
Strong Buy
3 Strong Buy rating(s)
2 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
17 Buy rating(s)
15 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$817.67$829.41$839.79$1,108.45
Forecasted Upside40.81% Upside48.41% Upside72.14% Upside-6.44% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Regeneron Pharmaceuticals Stock vs. The Competition

TypeRegeneron PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside40.81% Upside15,803.65% Upside10.22% Upside
News Sentiment Rating
Positive News

See Recent REGN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/27/2025Sanford C. Bernstein
4 of 5 stars
William Pickering
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$753.00 ➝ $781.00+32.88%
8/27/2025Jefferies Financial Group
2 of 5 stars
Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$813.00 ➝ $831.00+41.41%
8/14/2025Redburn Atlantic
5 of 5 stars
 UpgradeStrong-Buy
8/14/2025Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$890.00+58.49%
8/11/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Srikripa Devarakonda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$940.00 ➝ $812.00+45.12%
8/4/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan David
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$600.00 ➝ $640.00+12.85%
8/4/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform ➝ Sector Perform$688.00 ➝ $695.00+21.99%
8/1/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Yatin Suneja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$810.00 ➝ $815.00+49.42%
8/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$580.00+6.33%
8/1/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$754.00 ➝ $761.00+39.52%
8/1/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geoff Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$650.00+19.17%
7/23/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00+48.36%
6/30/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/9/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Schott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$950.00 ➝ $800.00+59.33%
4/30/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Salveen Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$917.00 ➝ $804.00+36.25%
4/25/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Skorney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$759.00 ➝ $652.00+8.71%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$695.00+23.78%
4/17/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tim Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderperform ➝ Underperform$575.00 ➝ $547.00-0.42%
2/5/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/5/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$762.00 ➝ $834.00+19.65%
2/4/2025Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$1,070.00 ➝ $1,000.00+44.18%
1/27/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$1,195.00 ➝ $1,013.00+47.20%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$1,150.00+46.96%
11/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$1,150.00 ➝ $1,000.00+20.56%
11/1/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,080.00 ➝ $1,065.00+25.91%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$1,250.00 ➝ $1,175.00+24.93%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,030.00 ➝ $1,200.00+12.39%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$800.00-2.77%
11/3/2023Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$950.00+16.02%
9/15/2023Westpark Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:06 AM ET.


Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 30, 2025. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • Regeneron Pharmaceuticals, Inc. has a solid revenue growth of over 3% compared to the same quarter last year, showcasing its ability to expand its market presence.
  • The current stock price is around $580, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • With a low debt-to-equity ratio, the company demonstrates strong financial health, suggesting it is less reliant on borrowed funds to finance its operations.
  • The company has a consistent dividend payout, with a yield of approximately 0.6%, providing investors with a steady income stream.

Regeneron Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • Despite recent earnings success, the stock has experienced volatility, which may deter risk-averse investors.
  • Analysts have mixed ratings on the stock, with some suggesting a "Hold" position, indicating uncertainty about future performance.
  • The company faces competition in the biopharmaceutical market, which could impact its market share and profitability.
  • Regeneron Pharmaceuticals, Inc. has a relatively low beta, suggesting it may not perform as well in a rising market compared to higher beta stocks.
  • Recent price target adjustments by analysts indicate a cautious outlook, which may signal potential challenges ahead for the company.

REGN Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $817.67, with a high forecast of $1,175.00 and a low forecast of $547.00.

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 17 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.

According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 40.81% based on their 12-month stock forecasts.

Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 downgrades and 1 upgrade by analysts.

Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.81 while the average consensus rating score for "medical" companies is 2.78. Learn more on how REGN compares to other companies.


This page (NASDAQ:REGN) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners